Clinical and Parasitological Protection in a Leishmania infantum-Macaque Model Vaccinated with Adenovirus and the Recombinant A2 Antigen

PLoS Neglected Tropical Diseases

Volumn 8, Issue 6, 2014, Pages

  Grimaldi Jr , Gabriel ^a   Teva, Antonio ^a   Porrozzi, Renato ^a   Pinto, Marcelo A ^a   Marchevsky, Renato S ^b   Rocha, Maria Gabrielle L ^c   Dutra, Miriam S ^a,c   Bruña Romero, Oscar ^d   Fernandes, Ana Paula ^c   Gazzinelli, Ricardo T ^a,c,e  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUMINUM POTASSIUM SULFATE; ASPARTATE AMINOTRANSFERASE; IMMUNOGLOBULIN G; RECOMBINANT A2 ANTIGEN; RECOMBINANT ANTIGEN; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT VACCINE;

ADENOVIRUS; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIARRHEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HISTOPATHOLOGY; LEISHMANIA INFANTUM; LIVER BIOPSY; MALE; NONHUMAN; PARASITE LOAD; REAL TIME POLYMERASE CHAIN REACTION; RHESUS MONKEY; VACCINATION; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; BLOOD; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; IMMUNOLOGY; LEISHMANIASIS; LIVER; MACACA; PARASITOLOGY; PATHOLOGY; PROCEDURES;

ADENOVIRUSES, HUMAN; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN G; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER; MACACA; MALE; PARASITE LOAD; PROTOZOAN VACCINES; VACCINATION; VACCINES, SYNTHETIC;

EID: 84903441379     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002853     Document Type: Article

References (54)

1. Lukes J, Mauricio IL, Schonian G, Dujardin JC, Soteriadou K, et al. (2007) Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci U S A 104: 9375-9380.
2. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671.
3. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, et al. (1986) New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 154: 1003-1011.
4. Badaro R, Jones TC, Lorenco R, Cerf BJ, Sampaio D, et al. (1986) A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis 154: 639-649.
5. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW, (1994) Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51: 826-836.
6. Pearson RD, Sousa AQ, (1996) Clinical spectrum of Leishmaniasis. Clin Infect Dis 22: 1-13.
7. Wilson ME, Jeronimo SM, Pearson RD, (2005) Immunopathogenesis of infection with the visceralizing Leishmania species. Microb Pathog 38: 147-160.
8. Blackwell JM, Mohamed HS, Ibrahim ME, (2004) Genetics and visceral leishmaniasis in the Sudan: seeking a link. Trends Parasitol 20: 268-274.
9. Davies CR, Mazloumi Gavgani AS, (1999) Age, acquired immunity and the risk of visceral leishmaniasis: a prospective study in Iran. Parasitology 119 (Pt 3): 247-257.
10. Cerf BJ, Jones TC, Badaro R, Sampaio D, Teixeira R, et al. (1987) Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 156: 1030-1033.
11. Murray HW, (1999) Kala-azar as an AIDS-related opportunistic infection. AIDS Patient Care STDS 13: 459-465.
12. Romero GA, Boelaert M, (2010) Control of visceral leishmaniasis in latin america-a systematic review. PLoS Negl Trop Dis 4: e584.
13. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
14. Kaye PM, Aebischer T, (2011) Visceral leishmaniasis: immunology and prospects for a vaccine. Clin Microbiol Infect 17: 1462-1470.
15. Quinnell RJ, Courtenay O, (2009) Transmission, reservoir hosts and control of zoonotic visceral leishmaniasis. Parasitology 136: 1915-1934.
16. Coler RN, Reed SG, (2005) Second-generation vaccines against leishmaniasis. Trends Parasitol 21: 244-249.
17. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, et al. (2009) Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27: 4747-4753.
18. Robinson HL, Amara RR, (2005) T cell vaccines for microbial infections. Nat Med 11: S25-32.
19. Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, et al. (2010) Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 28: 597-603.
20. Bongiorno G, Paparcone R, Foglia Manzillo V, Oliva G, Cuisinier AM, et al. (2013) Vaccination with LiESP/QA-21 (CaniLeish(R)) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs-a preliminary xenodiagnosis study. Vet Parasitol 197: 691-695.
21. Working Group on Research Priorities for Development of Leishmaniasis V, Costa CH, Peters NC, Maruyama SR, de Brito EC, Jr., et al (2011) Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl Trop Dis 5: e943.
22. Ghosh A, Zhang WW, Matlashewski G, (2001) Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20: 59-66.
23. Fernandes AP, Coelho EA, Machado-Coelho GL, Grimaldi G Jr, Gazzinelli RT, (2012) Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr Opin Microbiol 15: 476-485.
24. Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, et al. (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infection and Immunity 71: 3988-3994.
25. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, et al. (2007) Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 9: 1070-1077.
26. Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, et al. (2008) Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells. Vaccine 26: 4585-4593.
27. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, et al. (2009) Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28: 53-62.
28. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, et al. (2008) Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26: 5888-5895.
29. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, et al. (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178: 92-100.
30. Grimaldi G, (2008) The utility of rhesus monkey (Macaca mulatta) and other non-human primate models for preclinical testing of Leishmania candidate vaccines- A Review. Memorias Do Instituto Oswaldo Cruz 103: 629-644.
31. Carvalho FA, Charest H, Tavares CA, Matlashewski G, Valente EP, et al. (2002) Diagnosis of American visceral leishmaniasis in humans and dogs using the recombinant Leishmania donovani A2 antigen. Diagn Microbiol Infect Dis 43: 289-295.
32. Ramiro MJ, Zarate JJ, Hanke T, Rodriguez D, Rodriguez JR, et al. (2003) Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine 21: 2474-2484.
33. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, et al. (2006) Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17: 898-908.
34. Amaral VF, Ransatto VA, Conceicao-Silva F, Molinaro E, Ferreira V, et al. (1996) Leishmania amazonensis: the Asian rhesus macaques (Macaca mulatta) as an experimental model for study of cutaneous leishmaniasis. Exp Parasitol 82: 34-44.
35. Porrozzi R, Pereira MS, Teva A, Volpini AC, Pinto MA, et al. (2006) Leishmania infantum-induced primary and challenge infections in rhesus monkeys (Macaca mulatta): a primate model for visceral leishmaniasis. Trans R Soc Trop Med Hyg 100: 926-937.
36. Towbin H, Staehelin T, Gordon J, (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76: 4350-4354.
37. Vitale F, Reale S, Vitale M, Petrotta E, Torina A, et al. (2004) TaqMan-based detection of Leishmania infantum DNA using canine samples. Ann N Y Acad Sci 1026: 139-143.
38. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, et al. (2002) A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 20: 1226-1231.
39. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, et al. (2008) Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26: 333-344.
40. Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, et al. (2008) Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38: 706-719.
41. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D, (2005) Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infection and Immunity 73: 5286-5289.
42. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, et al. (1999) Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 163: 4481-4488.
43. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, et al. (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infection and Immunity 69: 4103-4108.
44. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, et al. (2001) Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infection and Immunity 69: 245-251.
45. Moreno J, Nieto J, Masina S, Canavate C, Cruz I, et al. (2007) Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25: 5290-5300.
46. Maglione PJ, Chan J, (2009) How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 39: 676-686.
47. Murray HW, (2001) Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 82: 249-267.
48. Lammas DA, De Heer E, Edgar JD, Novelli V, Ben-Smith A, et al. (2002) Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway. Int J Exp Pathol 83: 1-20.
49. Anderson CF, Oukka M, Kuchroo VJ, Sacks D, (2007) CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
50. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
51. Souza-Lemos C, de-Campos SN, Teva A, Porrozzi R, Grimaldi G Jr, (2011) In situ characterization of the granulomatous immune response with time in nonhealing lesional skin of Leishmania braziliensis-infected rhesus macaques (Macaca mulatta). Vet Immunol Immunopathol 142: 147-155.
52. Santana CC, Vassallo J, de Freitas LA, Oliveira GG, Pontes-de-Carvalho LC, et al. (2008) Inflammation and structural changes of splenic lymphoid tissue in visceral leishmaniasis: a study on naturally infected dogs. Parasite Immunol 30: 515-524.
53. Silva JS, Andrade AC, Santana CC, Santos LQ, Oliveira CI, et al. (2012) Low CXCL13 expression, splenic lymphoid tissue atrophy and germinal center disruption in severe canine visceral leishmaniasis. PLoS One 7: e29103.
54. Mebius RE, Kraal G, (2005) Structure and function of the spleen. Nat Rev Immunol 5: 606-616.